Results 91 to 100 of about 21,385 (196)

AB‐MDMSBA—Not a Synthetic Cannabinoid Receptor Agonist

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
This study uses classical in vitro pharmacology approaches to establish that AB‐MDMSBA does not bind to or activate the cannabinoid CB1 receptor and therefore should not be classified as a synthetic cannabinoid receptor agonist. ABSTRACT Synthetic cannabinoids remain one of the most prominent classes of New Psychoactive Substances (NPS).
Monica Patel   +4 more
wiley   +1 more source

Modulation of the endocannabinoid system reduces inflammatory signalling in canine mammary carcinoma cells

open access: yesVeterinary Record Open, Volume 13, Issue 1, June 2026.
Abstract Background Canine mammary carcinoma (CMC) is characterised by a chronic inflammatory microenvironment resembling human breast cancer; however, the upstream regulatory mechanisms driving this phenotype remain unclear. The endocannabinoid system (ECS) has emerged as a potential modulator of inflammation and tumour biology.
Gianluca Antonio Franco   +8 more
wiley   +1 more source

Hippocampal subfield differences in people with and without recreational ketamine use: Insights from multi‐modal neuroimaging

open access: yesAddiction, Volume 121, Issue 6, Page 1541-1556, June 2026.
Abstract Background and aims Recreational ketamine use has increased globally and is associated with psychiatric and cognitive concerns. The hippocampus in preclinical models shows damage and working‐memory disruption with repeated dosing. However, whether specific hippocampal subregions may differ in people with chronic ketamine use remains unclear ...
Yi‐Hsuan Liu   +8 more
wiley   +1 more source

Cannabinoid receptor-1 antagonism: a new perspective on treating a murine schistosomal liver fibrosis model

open access: yesMemorias do Instituto Oswaldo Cruz
BACKGROUND Formation of schistosomal granulomata surrounding the ova can result in schistosomiasis-associated liver fibrosis (SSLF). The current standard of treatment is praziquantel (PZQ), which cannot effectively reverse SSLF.
Yasmine Amr Issa   +2 more
doaj   +1 more source

Adolescent cannabis use and psychological distress from 2013 to 2023: A population‐based study in Ontario, Canada

open access: yesAddiction, Volume 121, Issue 6, Page 1495-1507, June 2026.
Abstract Background and aims Epidemiologic research suggests that adolescent cannabis use is associated with psychological distress (i.e. depression and anxiety symptoms); however, most studies have relied on 20th‐century data, when cannabis was significantly less potent than today.
André J. McDonald   +12 more
wiley   +1 more source

Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 12, Page 3173-3194, June 2026.
Cannabidiol (CBD) and cannabigerol (CBG) alleviate hepatic steatosis in obese mice by shifting energy buffering towards phosphocreatine and enhancing lysosomal lipid degradation and trafficking. These effects are associated with increased creatine kinase activity and lysobisphosphatidic acid (LBPA) levels, highlighting a previously unrecognised ...
Radka Kočvarová   +12 more
wiley   +1 more source

Neuroglial CB1 receptors modulate hippocampal processes in a sex-dependent manner

open access: yesBiology of Sex Differences
Background Navigation and memory are hippocampal functions that are essential for survival. One of the key modulators of hippocampal activity is the endocannabinoid system through the cannabinoid receptor type 1 (CB1).
Jon Egaña-Huguet   +14 more
doaj   +1 more source

The endogenous cannabinoid system gates plasticity of tonic GABA inhibition

open access: yesThe Journal of Physiology, Volume 604, Issue 12, Page 4984-5010, 15 June 2026.
Abstract figure legend Postsynaptic depolarisation and increases in intracellular Ca2+ ([Ca2+]i) trigger the synthesis of endocannabinoids (eCBs), which are hypothesised to enhance tonic GABAergic inhibition via two primary pathways. In the proposed autocrine mechanism, eCBs activate postsynaptic somatodendritic or mitochondrial CB1 receptors ...
Roberto Colangeli, Fiorenzo Conti
wiley   +1 more source

Coactivation of CB1 and GPR55 promotes GABA release and motor behavior at striatonigral terminals through increased dimerization induced by CB1 activation

open access: yesFrontiers in Molecular Neuroscience
CB1 and GPR55 receptors form heteromers in striatal neurons; however, the effects of these heteromers on GABA release at their terminals and their impact on motor behavior remain unknown. In this study, we investigate the presence of CB1-GPR55 heteromers
José Arturo Avalos-Fuentes   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy